NMD4C Launch Canadian Neuromuscular Clinical Trial Database
The NMD4C are excited to launch the The Canadian Neuromuscular Clinical Trial Database to provide a comprehensive and reliable landscape of Canadian neuromuscular clinical trials. The trial database is an initiative of the NMD4C Clinical Trial Network (CTN) created in collaboration with Canadian neuromuscular clinical trial site teams. Monthly updates are provided by clinical research coordinators working at Canadian trial sites, ensuring the most current information is always available.
The Canadian Neuromuscular Clinical Trial Database has been designed to meet the needs of Canadian neuromuscular trial community stakeholders.
- Providing accurate and up-to-date information: Our database provides reliable details about recruiting and not yet recruiting neuromuscular clinical trials, including clinical trial site locations and contact information.
- Fostering collaboration: Enables investigators to identify other sites conducting the same trial at different locations, fostering collaboration to address challenges and share best practices,
- Streamlining patient referral: Can be used as a tool to facilitate patient referral to appropriate clinical trials and/or clinical sites.
The database will continue to be updated and expanded. If you have any questions about the Canadian Neuromuscular Clinical Trial Database or would like to add your site to our list, please contact CTN manager Dr. Maria Masnata.
The NMD4C CTN is led by Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, with the objectives of increasing the number of clinical trials in Canada, enhance Canadian sites’ trial capacity, and support a cohesive network of clinician researchers and their teams.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.